. Author manuscript; available in PMC: 2010 Jan 1.

Published in final edited form as: Leukemia. 2009 Feb 19;23(7):1337–1341. doi: 10.1038/leu.2009.26

Table 4.

Comparison of CyborD response rates to other treatment regimens for newly diagnosed multiple myeloma

Regimen	Thal-Dex⁸	Len-Dex¹³	Bor-Dex¹⁴	MPT³³	VTD¹⁶	Bor-MP⁹	CyBorD
CR/nCR	8%	N/A	22%	16%	36%	33%	39%
≥VGPR	43%	44%	47%	29%	60%	41%	61%

Abbreviations: CR, complete response; nCR, near complete response, VGPR, very good partial response; MM, multiple myeloma; Thal-Dex, thalidomide-dexamethasone; Len-Dex, lenalidomide-dexamethasone; Bor-Dex, bortezomib-dexamethasone; MPT, melphalan, prednisone and thalidomide; VTD, Velcade©, thalidomide and dexamethasone; Bor-MP, bortezomib, melphalan and prednisone